SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT02977780

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : - Abemaciclib - Temozolomide (temodar) - Neratinib - CC115

NCT02977780 Glioblastoma
HPO:Glioblastoma multiforme

4 Interventions

Name: Temozolomide

Description: Temzolomide capsules
Type: Drug
Group Labels: 3

Abemaciclib with Temozolomide Neratinib with Temozolomide Temozolomide

Name: Neratinib

Description: Neratinib tablets
Type: Drug
Group Labels: 1

Neratinib with Temozolomide

Name: CC-115

Description: CC-115 capsule
Type: Drug
Group Labels: 1


Name: Abemaciclib

Description: Abemaciclib capsules
Type: Drug
Group Labels: 1

Abemaciclib with Temozolomide

Primary Outcomes

Measure: Overall Survival in Experimental Arms Compared with Standard Therapy

Time: 2 years

Secondary Outcomes

Description: Safety will be assessed by quantifying the toxicities and grades experienced by subjects, including serious adverse events (SAEs). The following will also be measured as part of safety: laboratory safety assessments, KPS status, vital signs and physical examinations.

Measure: Incidence of Treatment-Emergent Adverse Events

Time: 2 years

Measure: Progression Free Survival Among Experimental Arms And Biomarker Groups

Time: 2 years

Measure: Overall Survival Among Experimental Arms And Biomarker Groups

Time: 2 years

Measure: Association Between Progression Free Survival and Overall Survival Effects Of Experimental Agents

Time: 2 years

Purpose: Treatment

Allocation: Randomized

Parallel Assignment

There is one SNP


1 R132H

- Immunohistochemically negative for IDH1 R132H mutation. --- R132H ---

HPO Nodes